Hillary Lum
Concepts (392)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Advance Care Planning | 45 | 2024 | 202 | 16.240 |
Why?
| | Palliative Care | 19 | 2025 | 738 | 3.890 |
Why?
| | Patient Portals | 7 | 2024 | 45 | 3.180 |
Why?
| | Dementia | 6 | 2025 | 252 | 2.400 |
Why?
| | Primary Health Care | 15 | 2024 | 1756 | 2.120 |
Why?
| | Patient Participation | 6 | 2024 | 423 | 2.090 |
Why?
| | Caregivers | 13 | 2025 | 872 | 2.010 |
Why?
| | Hospice Care | 5 | 2023 | 201 | 1.850 |
Why?
| | Terminal Care | 6 | 2023 | 224 | 1.820 |
Why?
| | Aged | 64 | 2025 | 23798 | 1.800 |
Why?
| | Physicians | 9 | 2024 | 904 | 1.770 |
Why?
| | Suicide, Assisted | 6 | 2024 | 25 | 1.770 |
Why?
| | Communication | 15 | 2024 | 874 | 1.660 |
Why?
| | Advance Directives | 9 | 2024 | 70 | 1.650 |
Why?
| | Skilled Nursing Facilities | 7 | 2024 | 131 | 1.620 |
Why?
| | Physician-Patient Relations | 9 | 2024 | 552 | 1.600 |
Why?
| | Huntington Disease | 2 | 2024 | 57 | 1.550 |
Why?
| | Electronic Health Records | 7 | 2024 | 1040 | 1.430 |
Why?
| | Documentation | 5 | 2024 | 189 | 1.330 |
Why?
| | Aged, 80 and over | 26 | 2025 | 7593 | 1.270 |
Why?
| | Parkinson Disease | 3 | 2020 | 495 | 1.260 |
Why?
| | Humans | 122 | 2025 | 137514 | 1.260 |
Why?
| | Pandemics | 7 | 2022 | 1619 | 1.220 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 386 | 1.210 |
Why?
| | Volunteers | 2 | 2019 | 30 | 1.210 |
Why?
| | Surveys and Questionnaires | 21 | 2024 | 5772 | 1.200 |
Why?
| | Subacute Care | 5 | 2024 | 77 | 1.190 |
Why?
| | Hospices | 2 | 2022 | 87 | 1.150 |
Why?
| | Antibodies, Monoclonal | 9 | 2024 | 1428 | 1.140 |
Why?
| | Loneliness | 2 | 2025 | 44 | 1.120 |
Why?
| | Social Isolation | 2 | 2025 | 62 | 1.120 |
Why?
| | Heart Failure | 7 | 2023 | 2222 | 1.100 |
Why?
| | Quality Improvement | 6 | 2023 | 1161 | 1.070 |
Why?
| | Qualitative Research | 14 | 2024 | 1361 | 0.970 |
Why?
| | Home Care Services | 5 | 2023 | 254 | 0.960 |
Why?
| | Male | 57 | 2025 | 67718 | 0.910 |
Why?
| | Female | 62 | 2025 | 73162 | 0.880 |
Why?
| | Authorship | 1 | 2024 | 52 | 0.870 |
Why?
| | Home Health Aides | 1 | 2023 | 6 | 0.860 |
Why?
| | Medical Marijuana | 3 | 2020 | 117 | 0.830 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 72 | 0.830 |
Why?
| | Medicare | 5 | 2024 | 747 | 0.810 |
Why?
| | Life Support Care | 2 | 2020 | 32 | 0.810 |
Why?
| | Group Processes | 2 | 2020 | 62 | 0.790 |
Why?
| | Health Services for the Aged | 2 | 2020 | 73 | 0.780 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2020 | 1332 | 0.770 |
Why?
| | Antibodies, Neutralizing | 1 | 2024 | 282 | 0.760 |
Why?
| | Middle Aged | 28 | 2025 | 33355 | 0.740 |
Why?
| | Feasibility Studies | 3 | 2024 | 950 | 0.730 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1312 | 0.700 |
Why?
| | Patient Care Team | 3 | 2021 | 629 | 0.700 |
Why?
| | Living Wills | 1 | 2020 | 7 | 0.700 |
Why?
| | Outpatients | 2 | 2024 | 393 | 0.690 |
Why?
| | Housing | 1 | 2022 | 146 | 0.690 |
Why?
| | Music Therapy | 1 | 2020 | 25 | 0.680 |
Why?
| | Patient-Centered Care | 3 | 2021 | 527 | 0.680 |
Why?
| | Alzheimer Disease | 2 | 2025 | 559 | 0.670 |
Why?
| | Mass Screening | 2 | 2025 | 1264 | 0.670 |
Why?
| | Music | 1 | 2020 | 46 | 0.660 |
Why?
| | Inservice Training | 2 | 2017 | 113 | 0.640 |
Why?
| | Virtual Reality | 1 | 2020 | 62 | 0.640 |
Why?
| | Neurodegenerative Diseases | 1 | 2021 | 137 | 0.620 |
Why?
| | Ambulatory Care Facilities | 2 | 2019 | 233 | 0.620 |
Why?
| | Internship and Residency | 2 | 2021 | 1131 | 0.620 |
Why?
| | Pharmacists | 1 | 2021 | 260 | 0.610 |
Why?
| | CD40 Antigens | 4 | 2006 | 89 | 0.600 |
Why?
| | Sports | 1 | 2021 | 229 | 0.590 |
Why?
| | Resuscitation Orders | 4 | 2024 | 44 | 0.590 |
Why?
| | Attitude of Health Personnel | 7 | 2024 | 1169 | 0.590 |
Why?
| | Stakeholder Participation | 1 | 2019 | 77 | 0.590 |
Why?
| | Activities of Daily Living | 1 | 2022 | 414 | 0.580 |
Why?
| | Independent Living | 2 | 2018 | 102 | 0.580 |
Why?
| | Hospitalization | 5 | 2023 | 2197 | 0.570 |
Why?
| | Long-Term Care | 3 | 2024 | 100 | 0.560 |
Why?
| | Geriatric Assessment | 2 | 2024 | 214 | 0.560 |
Why?
| | Betacoronavirus | 1 | 2020 | 268 | 0.550 |
Why?
| | Patient Discharge | 5 | 2024 | 895 | 0.540 |
Why?
| | Nursing Homes | 4 | 2024 | 167 | 0.540 |
Why?
| | Geriatrics | 3 | 2024 | 88 | 0.530 |
Why?
| | Clinical Protocols | 1 | 2018 | 268 | 0.520 |
Why?
| | Physicians, Primary Care | 1 | 2019 | 236 | 0.520 |
Why?
| | Perception | 2 | 2020 | 360 | 0.520 |
Why?
| | Interviews as Topic | 5 | 2024 | 767 | 0.510 |
Why?
| | Social Media | 1 | 2019 | 157 | 0.500 |
Why?
| | Nurse Practitioners | 1 | 2018 | 135 | 0.500 |
Why?
| | Marijuana Use | 4 | 2020 | 203 | 0.490 |
Why?
| | Patient Education as Topic | 5 | 2019 | 766 | 0.480 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.470 |
Why?
| | Coronavirus Infections | 1 | 2020 | 359 | 0.470 |
Why?
| | Policy | 1 | 2016 | 150 | 0.470 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 126 | 0.460 |
Why?
| | Drug Utilization | 1 | 2015 | 170 | 0.450 |
Why?
| | Life Change Events | 1 | 2015 | 153 | 0.440 |
Why?
| | Health Services Accessibility | 2 | 2021 | 976 | 0.440 |
Why?
| | Patient Care Planning | 3 | 2020 | 155 | 0.430 |
Why?
| | Pilot Projects | 7 | 2025 | 1703 | 0.430 |
Why?
| | Patient Readmission | 4 | 2021 | 696 | 0.420 |
Why?
| | Education, Medical | 1 | 2017 | 260 | 0.420 |
Why?
| | Physician's Role | 1 | 2015 | 206 | 0.420 |
Why?
| | United States | 14 | 2025 | 14696 | 0.420 |
Why?
| | Cross-Sectional Studies | 6 | 2024 | 5427 | 0.410 |
Why?
| | Decision Making | 4 | 2017 | 906 | 0.410 |
Why?
| | Quality Assurance, Health Care | 1 | 2015 | 324 | 0.410 |
Why?
| | Nurses | 1 | 2015 | 174 | 0.390 |
Why?
| | Emergency Medical Services | 1 | 2018 | 548 | 0.370 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2054 | 0.360 |
Why?
| | Canada | 5 | 2023 | 421 | 0.360 |
Why?
| | Culture | 1 | 2012 | 131 | 0.360 |
Why?
| | Melanoma, Experimental | 3 | 2006 | 113 | 0.360 |
Why?
| | Quality of Life | 3 | 2023 | 2870 | 0.350 |
Why?
| | Interpersonal Relations | 1 | 2014 | 411 | 0.340 |
Why?
| | Health Status | 1 | 2016 | 784 | 0.340 |
Why?
| | Patients | 1 | 2012 | 175 | 0.340 |
Why?
| | Health Information Exchange | 2 | 2021 | 22 | 0.340 |
Why?
| | Depression | 3 | 2018 | 1408 | 0.340 |
Why?
| | Telemedicine | 4 | 2025 | 852 | 0.330 |
Why?
| | Retrospective Studies | 7 | 2024 | 15628 | 0.330 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1241 | 0.320 |
Why?
| | Adult | 13 | 2024 | 37821 | 0.320 |
Why?
| | Electronic Mail | 2 | 2019 | 61 | 0.310 |
Why?
| | Health Communication | 2 | 2019 | 43 | 0.290 |
Why?
| | Influenza, Human | 1 | 2014 | 632 | 0.280 |
Why?
| | Peer Group | 2 | 2020 | 244 | 0.280 |
Why?
| | Neuroblastoma | 2 | 2006 | 161 | 0.280 |
Why?
| | Hospital Mortality | 1 | 2012 | 902 | 0.280 |
Why?
| | Organizations, Nonprofit | 1 | 2007 | 17 | 0.270 |
Why?
| | Colorado | 9 | 2024 | 4521 | 0.270 |
Why?
| | Clinical Decision-Making | 2 | 2022 | 321 | 0.270 |
Why?
| | Social Work | 3 | 2024 | 84 | 0.260 |
Why?
| | Referral and Consultation | 4 | 2024 | 780 | 0.260 |
Why?
| | Health Resources | 1 | 2007 | 122 | 0.250 |
Why?
| | Automobile Driving | 2 | 2019 | 147 | 0.240 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 235 | 0.230 |
Why?
| | Immunotherapy | 2 | 2008 | 647 | 0.230 |
Why?
| | Immunization, Passive | 1 | 2005 | 90 | 0.230 |
Why?
| | Multimorbidity | 1 | 2025 | 47 | 0.220 |
Why?
| | Telerehabilitation | 1 | 2025 | 37 | 0.220 |
Why?
| | Antibodies, Bispecific | 1 | 2005 | 54 | 0.220 |
Why?
| | Oncologists | 1 | 2024 | 36 | 0.210 |
Why?
| | Internet | 2 | 2018 | 656 | 0.210 |
Why?
| | Neurology | 1 | 2025 | 114 | 0.210 |
Why?
| | Elder Abuse | 1 | 2024 | 51 | 0.210 |
Why?
| | Neoplasms | 3 | 2024 | 2666 | 0.210 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2113 | 0.210 |
Why?
| | T-Lymphocytes | 4 | 2006 | 1999 | 0.200 |
Why?
| | Sleep Aids, Pharmaceutical | 1 | 2022 | 4 | 0.200 |
Why?
| | Healthcare Disparities | 2 | 2021 | 651 | 0.200 |
Why?
| | Information Dissemination | 1 | 2024 | 218 | 0.190 |
Why?
| | Video Recording | 2 | 2025 | 184 | 0.190 |
Why?
| | Interleukin-2 | 3 | 2009 | 456 | 0.180 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2021 | 16 | 0.180 |
Why?
| | Death | 1 | 2022 | 119 | 0.180 |
Why?
| | Macrophages, Peritoneal | 3 | 2006 | 94 | 0.180 |
Why?
| | Endothelium, Vascular | 3 | 2011 | 923 | 0.180 |
Why?
| | Digital Divide | 1 | 2021 | 3 | 0.180 |
Why?
| | Macrophages | 2 | 2006 | 1548 | 0.180 |
Why?
| | Recovery of Function | 1 | 2025 | 662 | 0.180 |
Why?
| | HIV-1 | 1 | 2007 | 863 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1242 | 0.180 |
Why?
| | Nitric Oxide | 1 | 2006 | 914 | 0.170 |
Why?
| | Comorbidity | 2 | 2016 | 1618 | 0.170 |
Why?
| | Patient Selection | 1 | 2025 | 691 | 0.170 |
Why?
| | Deprescriptions | 1 | 2021 | 35 | 0.170 |
Why?
| | Hearing Loss | 1 | 2024 | 223 | 0.170 |
Why?
| | Personhood | 1 | 2020 | 5 | 0.170 |
Why?
| | Perioperative Care | 1 | 2022 | 182 | 0.170 |
Why?
| | Geriatric Psychiatry | 1 | 2020 | 12 | 0.170 |
Why?
| | Program Evaluation | 1 | 2025 | 892 | 0.170 |
Why?
| | Macrophage Activation | 3 | 2006 | 201 | 0.170 |
Why?
| | Multiple Chronic Conditions | 1 | 2020 | 28 | 0.170 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1066 | 0.170 |
Why?
| | Receptors, GABA-A | 1 | 2021 | 141 | 0.160 |
Why?
| | Health Expenditures | 1 | 2021 | 185 | 0.160 |
Why?
| | Organization and Administration | 1 | 2019 | 12 | 0.160 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 165 | 0.160 |
Why?
| | Cardiac Surgical Procedures | 1 | 2025 | 531 | 0.160 |
Why?
| | Health Plan Implementation | 1 | 2020 | 140 | 0.160 |
Why?
| | Patient Preference | 2 | 2022 | 190 | 0.160 |
Why?
| | Veterans | 2 | 2025 | 1461 | 0.160 |
Why?
| | Europe | 1 | 2020 | 414 | 0.160 |
Why?
| | Reimbursement Mechanisms | 1 | 2019 | 84 | 0.150 |
Why?
| | Software Design | 1 | 2018 | 24 | 0.150 |
Why?
| | Medical Futility | 1 | 2018 | 23 | 0.150 |
Why?
| | Recreation | 1 | 2018 | 23 | 0.150 |
Why?
| | Delphi Technique | 2 | 2017 | 273 | 0.150 |
Why?
| | Community-Institutional Relations | 1 | 2019 | 99 | 0.150 |
Why?
| | Inpatients | 1 | 2023 | 502 | 0.150 |
Why?
| | Patient Navigation | 1 | 2020 | 79 | 0.150 |
Why?
| | Prognosis | 2 | 2018 | 4031 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1580 | 0.150 |
Why?
| | Developed Countries | 1 | 2018 | 39 | 0.150 |
Why?
| | Vascular Diseases | 1 | 2001 | 244 | 0.150 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2018 | 18 | 0.140 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2006 | 225 | 0.140 |
Why?
| | Needs Assessment | 1 | 2020 | 368 | 0.140 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 258 | 0.140 |
Why?
| | Mentoring | 1 | 2020 | 144 | 0.140 |
Why?
| | Rural Population | 1 | 2022 | 567 | 0.140 |
Why?
| | Research Personnel | 1 | 2019 | 170 | 0.140 |
Why?
| | Prostatic Neoplasms | 1 | 2005 | 1034 | 0.130 |
Why?
| | Ecosystem | 1 | 2022 | 592 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2022 | 627 | 0.130 |
Why?
| | Reading | 1 | 2018 | 158 | 0.130 |
Why?
| | Program Development | 1 | 2019 | 366 | 0.130 |
Why?
| | Longitudinal Studies | 2 | 2016 | 2857 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2019 | 498 | 0.130 |
Why?
| | Brain Ischemia | 1 | 2020 | 341 | 0.130 |
Why?
| | Health Services Research | 1 | 2019 | 403 | 0.130 |
Why?
| | Universities | 1 | 2019 | 432 | 0.130 |
Why?
| | Community Health Services | 1 | 2018 | 232 | 0.130 |
Why?
| | Hypesthesia | 1 | 2016 | 17 | 0.130 |
Why?
| | Neoplasms, Experimental | 2 | 2008 | 176 | 0.130 |
Why?
| | Cannabis | 2 | 2020 | 490 | 0.120 |
Why?
| | Housing for the Elderly | 1 | 2015 | 7 | 0.120 |
Why?
| | Pain Management | 1 | 2019 | 363 | 0.120 |
Why?
| | Disease Management | 2 | 2019 | 625 | 0.120 |
Why?
| | Financing, Personal | 1 | 2015 | 26 | 0.120 |
Why?
| | Chest Pain | 1 | 2016 | 91 | 0.120 |
Why?
| | Terminology as Topic | 1 | 2017 | 216 | 0.120 |
Why?
| | Workflow | 1 | 2016 | 165 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 746 | 0.120 |
Why?
| | Prospective Studies | 4 | 2025 | 7598 | 0.120 |
Why?
| | Professional Role | 1 | 2016 | 165 | 0.120 |
Why?
| | Young Adult | 3 | 2021 | 13243 | 0.110 |
Why?
| | Environment | 1 | 2016 | 362 | 0.110 |
Why?
| | Firearms | 1 | 2020 | 376 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2001 | 1307 | 0.110 |
Why?
| | Curriculum | 1 | 2021 | 980 | 0.110 |
Why?
| | Family Practice | 1 | 2018 | 467 | 0.110 |
Why?
| | Cell Line, Tumor | 6 | 2009 | 3420 | 0.110 |
Why?
| | Communication Barriers | 1 | 2014 | 104 | 0.100 |
Why?
| | Cytokines | 4 | 2006 | 2095 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2016 | 354 | 0.100 |
Why?
| | Motivational Interviewing | 1 | 2015 | 104 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 1042 | 0.100 |
Why?
| | State Medicine | 1 | 2012 | 24 | 0.100 |
Why?
| | HIV Infections | 1 | 2007 | 2830 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1524 | 0.100 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 403 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 809 | 0.090 |
Why?
| | Stroke | 1 | 2020 | 1129 | 0.090 |
Why?
| | Attitude to Health | 1 | 2015 | 444 | 0.090 |
Why?
| | Glucuronidase | 1 | 2011 | 45 | 0.090 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2011 | 26 | 0.090 |
Why?
| | Benzodiazepines | 2 | 2022 | 153 | 0.090 |
Why?
| | Chronic Disease | 1 | 2017 | 1790 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2838 | 0.080 |
Why?
| | Respiratory Mechanics | 1 | 1990 | 67 | 0.080 |
Why?
| | Goals | 2 | 2022 | 168 | 0.080 |
Why?
| | Prevalence | 1 | 2016 | 2719 | 0.080 |
Why?
| | Mice, SCID | 2 | 2006 | 367 | 0.070 |
Why?
| | Killer Cells, Natural | 3 | 2006 | 446 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 619 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2008 | 665 | 0.070 |
Why?
| | Risk Factors | 3 | 2023 | 10356 | 0.070 |
Why?
| | Nigeria | 1 | 2007 | 22 | 0.070 |
Why?
| | Signal Transduction | 1 | 2001 | 5096 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 1990 | 405 | 0.070 |
Why?
| | Hyperglycemia | 1 | 2011 | 346 | 0.070 |
Why?
| | Adolescent | 3 | 2021 | 21555 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2020 | 10821 | 0.070 |
Why?
| | Immunologic Memory | 1 | 2009 | 369 | 0.070 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 258 | 0.070 |
Why?
| | Hospitals | 2 | 2022 | 678 | 0.070 |
Why?
| | Animals | 12 | 2011 | 37011 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2006 | 5792 | 0.070 |
Why?
| | Religion | 1 | 2007 | 69 | 0.070 |
Why?
| | Mice | 8 | 2009 | 17843 | 0.070 |
Why?
| | Atherosclerosis | 1 | 2011 | 415 | 0.070 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2006 | 48 | 0.060 |
Why?
| | Mice, Inbred A | 1 | 2006 | 49 | 0.060 |
Why?
| | Subcutaneous Tissue | 1 | 2006 | 24 | 0.060 |
Why?
| | Toll-Like Receptor 9 | 1 | 2006 | 32 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1115 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 300 | 0.060 |
Why?
| | Neoplasm Transplantation | 1 | 2006 | 256 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 241 | 0.060 |
Why?
| | Vaccination | 1 | 2014 | 1398 | 0.060 |
Why?
| | Mental Status and Dementia Tests | 1 | 2025 | 26 | 0.060 |
Why?
| | Preoperative Period | 1 | 2025 | 131 | 0.060 |
Why?
| | Antigen Presentation | 1 | 2006 | 216 | 0.060 |
Why?
| | Self Report | 2 | 2019 | 831 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3292 | 0.060 |
Why?
| | CD3 Complex | 1 | 2005 | 106 | 0.060 |
Why?
| | Conscience | 1 | 2024 | 7 | 0.060 |
Why?
| | Tumor Cells, Cultured | 1 | 2006 | 957 | 0.060 |
Why?
| | Postoperative Period | 1 | 2025 | 344 | 0.060 |
Why?
| | Lymphocyte Activation | 2 | 2006 | 1150 | 0.050 |
Why?
| | Immunoconjugates | 1 | 2005 | 116 | 0.050 |
Why?
| | Terminally Ill | 1 | 2023 | 37 | 0.050 |
Why?
| | Specialization | 1 | 2024 | 143 | 0.050 |
Why?
| | Epidemics | 1 | 2024 | 87 | 0.050 |
Why?
| | Preoperative Care | 1 | 2025 | 356 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 112 | 0.050 |
Why?
| | Morals | 1 | 2023 | 81 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 845 | 0.050 |
Why?
| | Pregnancy Proteins | 1 | 2002 | 36 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 561 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 886 | 0.050 |
Why?
| | Age Factors | 2 | 2020 | 3301 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2005 | 342 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2009 | 937 | 0.050 |
Why?
| | Patient Care | 1 | 2023 | 111 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2005 | 790 | 0.050 |
Why?
| | Cohort Studies | 1 | 2012 | 5730 | 0.050 |
Why?
| | Rats | 2 | 2011 | 5676 | 0.050 |
Why?
| | Asia | 1 | 2021 | 70 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 179 | 0.040 |
Why?
| | Neutrophils | 1 | 2006 | 1238 | 0.040 |
Why?
| | Senior Centers | 1 | 2019 | 1 | 0.040 |
Why?
| | Ownership | 1 | 2020 | 91 | 0.040 |
Why?
| | Thrombectomy | 1 | 2020 | 69 | 0.040 |
Why?
| | Leukocytes | 1 | 2001 | 311 | 0.040 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 287 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 357 | 0.040 |
Why?
| | Confidentiality | 1 | 2019 | 71 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2021 | 280 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2020 | 163 | 0.040 |
Why?
| | Safety | 1 | 2020 | 342 | 0.040 |
Why?
| | Professional-Patient Relations | 1 | 2019 | 145 | 0.040 |
Why?
| | Minority Health | 1 | 2018 | 20 | 0.040 |
Why?
| | Informed Consent | 1 | 2019 | 170 | 0.040 |
Why?
| | Social Values | 1 | 2018 | 37 | 0.040 |
Why?
| | Interdisciplinary Research | 1 | 2017 | 27 | 0.030 |
Why?
| | California | 1 | 2018 | 425 | 0.030 |
Why?
| | Internationality | 1 | 2017 | 155 | 0.030 |
Why?
| | Patient Safety | 1 | 2019 | 305 | 0.030 |
Why?
| | Students | 1 | 2021 | 625 | 0.030 |
Why?
| | Racism | 1 | 2018 | 137 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1286 | 0.030 |
Why?
| | Time Factors | 3 | 2020 | 6817 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3439 | 0.030 |
Why?
| | Personal Autonomy | 1 | 2015 | 48 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2025 | 2641 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2020 | 948 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2008 | 1185 | 0.030 |
Why?
| | Empathy | 1 | 2015 | 180 | 0.020 |
Why?
| | Pain | 1 | 2018 | 836 | 0.020 |
Why?
| | Spleen | 2 | 2004 | 516 | 0.020 |
Why?
| | Streptozocin | 1 | 2011 | 21 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 1041 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 1990 | 46 | 0.020 |
Why?
| | Gerbillinae | 1 | 1990 | 66 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 194 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 320 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 1989 | 82 | 0.020 |
Why?
| | Pressure | 1 | 1990 | 244 | 0.020 |
Why?
| | Albumins | 1 | 1989 | 114 | 0.020 |
Why?
| | Thrombin | 1 | 1989 | 152 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1989 | 260 | 0.020 |
Why?
| | Child | 1 | 2007 | 22037 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2066 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1271 | 0.020 |
Why?
| | Apoptosis | 2 | 2006 | 2557 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1241 | 0.020 |
Why?
| | Cell Division | 2 | 2002 | 795 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2009 | 349 | 0.020 |
Why?
| | Glucose | 1 | 2011 | 1018 | 0.020 |
Why?
| | Leukemia L5178 | 1 | 2005 | 1 | 0.020 |
Why?
| | CpG Islands | 1 | 2006 | 160 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2011 | 2501 | 0.010 |
Why?
| | Cell Line | 1 | 2011 | 2852 | 0.010 |
Why?
| | Jurkat Cells | 1 | 2005 | 134 | 0.010 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2008 | 868 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 272 | 0.010 |
Why?
| | Gangliosides | 1 | 2004 | 20 | 0.010 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2004 | 31 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2006 | 321 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2005 | 240 | 0.010 |
Why?
| | Cytoplasm | 1 | 2005 | 274 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2004 | 413 | 0.010 |
Why?
| | Ligands | 1 | 2005 | 665 | 0.010 |
Why?
| | Megakaryocytes | 1 | 2002 | 33 | 0.010 |
Why?
| | CHO Cells | 1 | 2002 | 161 | 0.010 |
Why?
| | Cricetinae | 1 | 2002 | 288 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 1035 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2004 | 659 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2002 | 313 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4295 | 0.010 |
Why?
| | Gestational Age | 1 | 2002 | 903 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2002 | 398 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1357 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2005 | 3020 | 0.010 |
Why?
| | Fetus | 1 | 2002 | 807 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2002 | 4206 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2002 | 1979 | 0.010 |
Why?
| | Pregnancy | 1 | 2002 | 6745 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 1989 | 402 | 0.000 |
Why?
| | Actins | 1 | 1989 | 416 | 0.000 |
Why?
| | Cattle | 1 | 1989 | 982 | 0.000 |
Why?
| | Cell Survival | 1 | 1989 | 1122 | 0.000 |
Why?
| | Cell Membrane | 1 | 1989 | 751 | 0.000 |
Why?
|
|
Lum's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|